Elsevier

Gynecologic Oncology

Volume 55, Issue 3, December 1994, Pages S4-S14
Gynecologic Oncology

Regular Article
National Institutes of Health Consensus Development Conference Statement

https://doi.org/10.1006/gyno.1994.1333Get rights and content

Abstract

The National Institutes of Health Consensus Development Conference on Ovarian Cancer—Screening, Treatment, and Follow-up brought together epidemiologists; obstetrician/gynecologists; gynecologic, medical, and radiation oncologists; and the public to address the following questions: (1) What is the current status of screening and prevention in ovarian cancer? (2) What is the appropriate management of early-stage ovarian cancer? (3) What is the appropriate management of advanced epithelial ovarian cancer? (4) What is the appropriate follow-up after primary therapy? and (5) What are the directions for future research? The consensus panel concluded that there is an evidence available as yet that the current screening modalities of CA 125 and transvaginal ultrasonography can be effectively used for widespread screening to reduce mortality from ovarian cancer nor that their use will result in decreased rather than increased morbidity and mortality. They recommended that further prospective research be done to evaluate this very important issue. Women with stage IA grade 1 and most IB grade 1 ovarian cancer do not require postoperative adjuvant therapy. Many remaining stage I patients do require chemotherapy. Subsets of stage I must be fully defined and ideal treatment must be determined. Women with stages II, III, and IV epithelial ovarian cancer (other than low malignant potential tumors) should receive postoperative chemotherapy. Physicians should be encouraged to discuss clinical trial participation with women, and women should be encouraged to participate. All women should have access to accurate and complete information regarding ovarian cancer. Furthermore, there must be no barriers to women's access to qualified specialists, optimal therapy, and protocols. The full text of the consensus panel's statement follows.

References (0)

Cited by (140)

  • Ovarian masses in the child and adolescent: An American Pediatric Surgical Association Outcomes and Evidence-Based Practice Committee systematic review

    2019, Journal of Pediatric Surgery
    Citation Excerpt :

    The infra-colic omentum should be removed…Pelvic and para-aortic lymph node sampling is part of surgical staging.” This protocol allows for the preservation of the uterus and the contralateral ovary in the case of a young patient with early disease who wishes to preserve reproductive potential [36,37]. The current surgical staging procedure for pediatric ovarian germ cell tumors has been outlined by the Children's Oncology Group (COG).

  • Cancer overturned: Endometrioma mimicking granulosa cell tumor and the importance of FOXL2 analysis

    2019, Gynecologic Oncology Reports
    Citation Excerpt :

    In the United States, it is estimated that the lifetime risk for surgery for a suspected ovarian neoplasm is 5–10% (National Institutes of Health Consensus Development Conference Statement, 1994).

  • Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass

    2018, Gynecologic Oncology
    Citation Excerpt :

    It is estimated that there is a 5–10% lifetime risk for a woman to undergo surgery for a suspected ovarian neoplasm [1].

View all citing articles on Scopus
View full text